Cargando…

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel

The present explorative study was initiated to evaluate the clinical value of (18)F-FES PET/CT in monitoring the change of estrogen receptor (ER) expression and potential predictive value in metastatic breast cancer patients. Twenty-two pathology-confirmed breast cancer patients were prospectively e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Chengcheng, Yang, Zhongyi, Sun, Yifei, Zhang, Jian, Zheng, Chunlei, Wang, Leiping, Zhang, Yongping, Xue, Jing, Yao, Zhifeng, Pan, Herong, Wang, Biyun, Zhang, Yingjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529439/ https://www.ncbi.nlm.nih.gov/pubmed/28747642 http://dx.doi.org/10.1038/s41598-017-06903-8

Ejemplares similares

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal (18)F-FES PET/CT
por: He, SiMin, et al.
Publicado: (2019)

The Preliminary Study of 16α-[18F]fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients
por: Sun, Yifei, et al.
Publicado: (2015)

Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
por: Liu, Cheng, et al.
Publicado: (2020)

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2019)

Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
por: Liu, Cheng, et al.
Publicado: (2022)

Pretreatment (18) F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma——a retrospective study
por: Yang, Zhongyi, et al.
Publicado: (2015)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results
por: Qi, Shi, et al.
Publicado: (2017)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
por: Ntekim, A.I., et al.
Publicado: (2010)

Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
por: Lim, Hyun-Kyung, et al.
Publicado: (2016)

A Comparison of Hepatocyte Cytotoxic Mechanisms for Docetaxel and PLGA-Docetaxel Nanoparticls
por: Daraei, Bahram, et al.
Publicado: (2017)

Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota
por: Liu, Qingya, et al.
Publicado: (2021)

The influence of nanocarrier architectures on antitumor efficacy of docetaxel nanoparticles
por: Dong, Zhengqi, et al.
Publicado: (2020)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Docetaxel-Aggravated Psoriasis
por: Yang, Seungkeol, et al.
Publicado: (2019)

Docetaxel-related interstitial pneumonitis
por: Wang, Chung-Jen, et al.
Publicado: (2015)

Epiphora in lung cancer patients receiving docetaxel: a case series
por: Yamagishi, Tomoko, et al.
Publicado: (2014)

How nanotechnology can enhance docetaxel therapy
por: Zhang, Li, et al.
Publicado: (2013)

Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
por: Lage, Daniel E., et al.
Publicado: (2021)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging
por: Bao, Xiao, et al.
Publicado: (2016)

Docetaxel-induced photolichenoid eruption
por: Vasudevan, Biju, et al.
Publicado: (2009)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study
por: Yang, Zhongyi, et al.
Publicado: (2013)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Docetaxel enhances lysosomal function through TFEB activation
por: Zhang, Jianbin, et al.
Publicado: (2018)

Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells
por: Deng, Leihong, et al.
Publicado: (2019)

Metabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits
por: Wang, Jie, et al.
Publicado: (2017)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
por: Scagliotti, G V, et al.
Publicado: (2006)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u779ri5p4vd8hspp80ii3fhiop